© РИА Томск. Яков Андреев
TOMSK, Jul
24 – RIA Tomsk. Specialists of the Tomsk сompany "Ifar" finished preclinical
tests of drug, which contains the new molecule allowing to regulate
coagulability of blood in the safest way; the drug is necessary for the people
having cardiovascular diseases, the innovative portal of the Tomsk region
reports on Monday.
It is noted
that the drugs regulating coagulability of blood are necessary for the people
who had strokes, infarcts, installation of stents surgeries, artificial valves.
Such patients take antiplatelet drugs all their lives therefore safety of drug
is of particular importance.
"We
can tell with confidence after tests that we found the effective molecule,
which has no competitors on harmlessness yet. This drug is a break for medicine
… It influences the mechanism of coagulability of blood differently, than
predecessors, affects a signal way which is launched by nitrogen oxide –
NO", – the general director of "Ifar" Veniamin Hazanov is quoted
in the message.
© РИА Томск. Павел Стефанский
The
molecule, opened by specialists of Ifar influences development of nitrogen
oxide in organism, which weakens spasmodic vessels and eliminates the ischemia
phenomena. The developers managed to include the molecule in composition of the
drug and to prove its efficiency and low toxicity, it is emphasized in the
message.
It is
specified that the drug passed preclinical tests at the moment, prototypes are
released. Ifar plans to bring the drug to clinical tests at the end of 2017 –
the beginning of 2018.